India Regulators Begin Final Review of Sputnik V Vaccine

Hyderabad - based Dr. Reddy’s Laboratories confirmed it had submitted phase 2 and 3 clinical study data to the Drug Controller General of India as requested and awaits final review. If approved, 100 million doses of the Sputnick V vaccine would become available in India, reported the Times of India on March 25, 2021.

Recently, India-based Gland Pharma Ltd. announced an agreement with the Russian Direct Investment Fund to produce and supply up to 25.2 doses of the Sputnik V vaccine during 2021.

In total, 56 countries had authorized the Sputnik V Vaccine as of March 25, 2021.

Research studies have shown the Sputnik V (Gam-COVID-Vac) vaccine reduces the time for the development of immunity to SARS-CoV-2, the beta coronavirus that causes COVID-19 in people.